COMMUNIQUÉS West-GlobeNewswire

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
13/05/2026
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of [...]
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
13/05/2026
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF [...]
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
13/05/2026
TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) ( “PharmAla” or the “Company” ), a leader in the research, development, and manufacturing of clinical-grade MDMA and [...]
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
13/05/2026
BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia
13/05/2026
ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in JAMA Network [...]
Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
13/05/2026
First-in-human study evaluates weekly IV Sapu003 in advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer, RCC, NETs, TSC-associated tumors, and HCC SAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- [...]
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
13/05/2026
64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non- [...]
Dyne Therapeutics to Participate in Upcoming Investor Conferences
13/05/2026
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
13/05/2026
MINNEAPOLIS and BRISBANE, Australia, May 13, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
13/05/2026
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary [...]
NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical
13/05/2026
Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL [...]
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
13/05/2026
Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of care First 45-subject data unblinding expected before June 30, 2026 Program targets [...]
HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026
13/05/2026
Tuebingen , Germany, May 13 , 202 6 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces that its abstract highlighting clinical [...]
Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors
13/05/2026
BASEL, Switzerland, May 13, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
Valneva publie ses résultats financiers audités et consolidés pour le premier trimestre 2026
13/05/2026
Ventes de produits de 30,5 millions d’euros Position de trésorerie de 105,3 millions d’euros à fin mars 2026, hors produit de la levée de fonds réservée réalisée avec succès en avril 2026 1 Lancement, en avril 2026, d’ [...]
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
13/05/2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced [...]
Bavarian Nordic Announces Interim Results for the First Three Months of 2026
13/05/2026
COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2026. Revenue for the first three months was DKK 1, [...]
IBA introduces AdaPTinsight XR, the next generation of CBCT imaging for image-guided proton therapy
13/05/2026
Proton therapy CBCT imaging solution across Proteus ® Portfolio providing clarity and confidence in IGPT Louvain-la-Neuve, Belgium, May 13, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle [...]
IBA lance AdaPTinsight XR, la nouvelle génération d’imagerie CBCT pour la protonthérapie guidée par l’image
13/05/2026
Une solution d’imagerie CBCT pour les systèmes de protonthérapie Proteus ® offrant une visibilité claire qui permet des traitements IGPT en toute confiance Louvain-la-Neuve, Belgique, le 13 mai 2026 – IBA (Ion Beam [...]

Pages